| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pinaki Dutta, Anil Bhansali, Kim Vaiphei, Usha Dutta, P Ravi Kumar, Shariq Masoodi, Kanchan Kumar Mukherjee, Alka Varma, R Kochha. Colonic neoplasia in acromegaly: increased proliferation or deceased apoptosis? Pituitary. vol 15. issue 2. 2012-09-21. PMID:21451936. |
we aimed to evaluate the proliferative and apoptotic markers in samples of colonic mucosa obtained during screening colonoscopic biopsy from patients with acromegaly and study their relationship to serum igf-1 and gh levels. |
2012-09-21 |
2023-08-12 |
human |
| Paul M Stewart, Mark Sherloc. Mortality and pituitary disease. Annales d'endocrinologie. vol 73. issue 2. 2012-09-14. PMID:22503666. |
control of cortisol secretion and growth hormone (gh) hypersecretion (together with cardiovascular risk factor reduction) is key in the normalisation of mortality rates in patients with cushing's disease and acromegaly, respectively, though some excess mortality may persist even in "cured" patients. |
2012-09-14 |
2023-08-12 |
Not clear |
| Eui Hyun Kim, Min Chul Oh, Eun Jig Lee, Sun Ho Ki. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly. Neurosurgery. vol 70. issue 5. 2012-09-13. PMID:22067418. |
the suppression of the growth hormone (gh) on an oral glucose tolerance test (ogtt) has been accepted as the most reliable parameter for determining remission of acromegaly. |
2012-09-13 |
2023-08-12 |
Not clear |
| Andrea Giustina, Gherardo Mazziotti, Valter Torri, Maurizio Spinello, Irene Floriani, Shlomo Melme. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PloS one. vol 7. issue 5. 2012-09-10. PMID:22574156. |
the long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (gh) levels in patients with acromegaly and may also induce pituitary tumor shrinkage. |
2012-09-10 |
2023-08-12 |
Not clear |
| Christopher R Palmeiro, Rishi Anand, Inderpreet Kaur Dardi, Nivas Balasubramaniyam, Monica D Schwarcz, Irene A Weis. Growth hormone and the cardiovascular system. Cardiology in review. vol 20. issue 4. 2012-08-28. PMID:22314142. |
acromegaly, a state of endogenous gh excess, results in myocardial hypertrophy and decreased cardiac performance with increased cardiovascular mortality. |
2012-08-28 |
2023-08-12 |
human |
| L Sze, R L Bernays, C Zwimpfer, P Wiesli, M Brändle, C Schmi. Excessively high soluble Klotho in patients with acromegaly. Journal of internal medicine. vol 272. issue 1. 2012-08-24. PMID:22452701. |
the aim of our study was to examine the relationship between excess growth hormone (gh) and serum levels of klotho in patients with acromegaly, a disease usually caused by a pituitary adenoma, which is associated with high phosphate levels and reduced life expectancy. |
2012-08-24 |
2023-08-12 |
mouse |
| G Minniti, C Scaringi, D Amelio, R Maurizi Enric. Stereotactic Irradiation of GH-Secreting Pituitary Adenomas. International journal of endocrinology. vol 2012. 2012-08-23. PMID:22518123. |
radiotherapy (rt) is often employed in patients with acromegaly refractory to medical and/or surgical interventions in order to prevent tumour regrowth and normalize elevated gh and igf-i levels. |
2012-08-23 |
2023-08-12 |
Not clear |
| Gloria Lugo, Lara Pena, Fernando Cordid. Clinical manifestations and diagnosis of acromegaly. International journal of endocrinology. vol 2012. 2012-08-23. PMID:22518126. |
acromegaly and gigantism are due to excess gh production, usually as a result of a pituitary adenoma. |
2012-08-23 |
2023-08-12 |
Not clear |
| Gloria Lugo, Lara Pena, Fernando Cordid. Clinical manifestations and diagnosis of acromegaly. International journal of endocrinology. vol 2012. 2012-08-23. PMID:22518126. |
it has been suggested that the rate of mortality in patients with acromegaly is correlated with the degree of control of gh. |
2012-08-23 |
2023-08-12 |
Not clear |
| E Diaz-Rodriguez, M García-Lavandeira, S Perez-Romero, A Senra, C Cañibano, I Palmero, M G Borrello, C Dieguez, C V Alvare. Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells. Oncogene. vol 31. issue 23. 2012-08-21. PMID:22020338. |
thus pit-1, a differentiation factor, activates the oncogene-induced apoptosis (oia) pathway as oncogenes exerting a tight control in somatotrophs to prevent the disease due to excess of gh (insulin-resistance, metabolic disease, acromegaly). |
2012-08-21 |
2023-08-12 |
Not clear |
| Marek Pawlikowski, Joanna Kuta, Julitta Fuss-Chmielewska, Katarzyna Winczy. 'Silent' somatotropinoma. Endokrynologia Polska. vol 63. issue 2. 2012-08-16. PMID:22538745. |
'silent' somatotropinomas are defined as gh-immunopositive pituitary adenomas without clinical symptoms of acromegaly and gh elevation in peripheral blood. |
2012-08-16 |
2023-08-12 |
Not clear |
| Hitoshi Nishizawa, Anastasia-Evi Handayaningsih, Genzo Iguchi, Yoshitake Cho, Michiko Takahashi, Masaaki Yamamoto, Kentaro Suda, Kohei Kasahara, Fumihiko Hakuno, Keitaro Yamanouchi, Masugi Nishihara, Susumu Seino, Shin-Ichiro Takahashi, Yutaka Takahash. Enhanced oxidative stress in GH-transgenic rat and acromegaly in humans. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 22. issue 2. 2012-08-08. PMID:22370764. |
acromegaly is a pathological condition associated with excess growth hormone (gh) and insulin-like growth factor-i (igf-i) and a high prevalence of diabetes, hypertension, atherosclerosis, and heart failure; resulting in premature death. |
2012-08-08 |
2023-08-12 |
rat |
| Elena Valassi, Danielle J Brick, Jessica C Johnson, Beverly M K Biller, Anne Klibanski, Karen K Mille. Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 18. issue 2. 2012-08-08. PMID:22440981. |
to compare the response in quality of life (qol) to growth hormone (gh) replacement in women with gh deficiency (ghd) and a history of acromegaly with that in women with ghd of other causes. |
2012-08-08 |
2023-08-12 |
Not clear |
| María J Garrido, Josep-María Cendrós, Joaquim Ramis, Concepción Peraire, Rosendo Obach, Iñaki F Trocóni. Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1. Journal of clinical pharmacology. vol 52. issue 4. 2012-07-27. PMID:21551318. |
acromegaly arises from excessive levels of growth hormone (gh), many of whose effects are mediated by stimulation of secretion of insulin-like growth factor 1 (igf-1). |
2012-07-27 |
2023-08-12 |
Not clear |
| María J Garrido, Josep-María Cendrós, Joaquim Ramis, Concepción Peraire, Rosendo Obach, Iñaki F Trocóni. Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1. Journal of clinical pharmacology. vol 52. issue 4. 2012-07-27. PMID:21551318. |
the objective of the study was to develop a population pharmacodynamic model describing the relationship between serum concentrations of lanreotide (c(p)) and its gh and igf-1 effects in patients with acromegaly receiving lanreotide autogel (la) at doses of 60, 90, or 120 mg by deep subcutaneous route every 28 days. |
2012-07-27 |
2023-08-12 |
Not clear |
| Fatih M Erdur, Türker Kilic, Selcuk Peker, Ozlem Celik, Pinar Kadiogl. Gammaknife radiosurgery in patients with acromegaly. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 18. issue 12. 2012-07-19. PMID:22001240. |
we concluded that gkr is an effective adjuvant treatment to control tumour growth, lower gh and igf-1 levels, and to increase remission rates in patients with acromegaly who were refractory to surgical and medical treatment. |
2012-07-19 |
2023-08-12 |
Not clear |
| Emilie Morin, France Berthelet, John Weisnagel, Martin Bidlingmaier, Omar Serr. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary. vol 15. issue 1. 2012-07-16. PMID:20407837. |
it has been suggested that treatment with adequate dose titration of pegvisomant, a gh antagonist, up to a maximum of 40 mg daily, can achieve igf-1 normalisation in virtually all patients with acromegaly. |
2012-07-16 |
2023-08-12 |
Not clear |
| Annamaria Cola. Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary. vol 15. issue 1. 2012-07-16. PMID:21713528. |
in acromegaly, growth hormone (gh) and insulin-like growth factor-1 (igf-1) excess results in a specific cardiomyopathy characterized by concentric cardiac hypertrophy primarily associated with diastolic dysfunction that can lead to impaired systolic function and eventually heart failure. |
2012-07-16 |
2023-08-12 |
Not clear |
| Vicky Cheng, Charles Faiman, Laurence Kennedy, Fadi Khoury, Betul Hatipoglu, Robert Weil, Amir Hamrahia. Pregnancy and acromegaly: a review. Pituitary. vol 15. issue 1. 2012-07-16. PMID:21789529. |
the diagnosis of acromegaly during pregnancy is made difficult due to the physiologic changes in pituitary gh secretion and igf-1 production resulting from placental gh secretion and the inability of commercial assays to discriminate between pituitary and placental gh. |
2012-07-16 |
2023-08-12 |
Not clear |
| A Hannemann, H Wallaschofski, R Rettig, H Völzke, S Samietz, M Nauck, M Bidlingmaier, N Friedric. Association of IGF-I and the IGF-I/IGFBP-3 ratio with plasma aldosterone levels in the general population. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 44. issue 3. 2012-07-12. PMID:22328165. |
several studies in patients with acromegaly or growth hormone (gh) deficiency suggest a stimulatory effect of the growth hormone (gh)/insulin-like growth factor i (igf-i) axis on the renin-angiotensin-aldosterone system (raas). |
2012-07-12 |
2023-08-12 |
human |